<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18378">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01980810</url>
  </required_header>
  <id_info>
    <org_study_id>CH-GI-037-nab</org_study_id>
    <nct_id>NCT01980810</nct_id>
  </id_info>
  <brief_title>First Line Chemotherapy for Advanced Cancer</brief_title>
  <acronym>GC-A-003</acronym>
  <official_title>Pase 2 Study of Albumin-bounded Paclitaxel Plus S-1 as First-line Chemotherapy for Locally Advanced or Metastatic Gastric or Gastro-esophageal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether albumine-bounded paclitaxel plus S-1 are
      effective in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase II study was designed to evaluate the efficacy and safety of albumin-bounded
      paclitaxel combined with S-1 as first-line chemotherapy for inoperable and /or metastatic
      gastric or gastroesophageal junction cancer.Primary endpoint was overall response rate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of adverse event</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>albumin-bounded paclitaxel plus S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>arm 1:albumin-bounded paclitaxel 200mg iv d1  and S-1 80mg/m2/d po d1-10, repeated every 2 weeks,up to 9 cycles,then S-1 as single agent to treat to disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albumin-bounded paclitaxel</intervention_name>
    <description>200mg iv d1,  repeat every 2 weeks,until disease progression,or up to 9 cycles</description>
    <arm_group_label>albumin-bounded paclitaxel plus S-1</arm_group_label>
    <other_name>Abraxane</other_name>
    <other_name>Paclitaxel Albumin-stabilized Nanoparticle Formulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>40mg/m2 po, bid,d1-10,repeated every 2 weeks until disease progression</description>
    <arm_group_label>albumin-bounded paclitaxel plus S-1</arm_group_label>
    <other_name>TS-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inoperable locally advanced, recurrent, and/or metastatic adenocarcinoma of the
             stomach or gastro-esophageal junction

          -  Adult patients &gt;=18 years of age

          -  Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-2;

          -  At least have one measurable disease(according to RECIST)

          -  Adequate bone marrow,renal and liver function

        Exclusion Criteria:

          -  Previous chemotherapy for advanced/metastatic disease

          -  Lack of physical integrity of the upper gastrointestinal tract, or malabsorption
             syndrome
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of medical oncology,Cancer hospital and institute,CAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Song, MD</last_name>
    <phone>010-87788145</phone>
    <email>song-yan@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medical Oncology,Cancer Hostpital and Institute,CAMS</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Song, MD</last_name>
      <phone>86-10-87788145</phone>
      <email>song-yan@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Lin Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 5, 2013</lastchanged_date>
  <firstreceived_date>November 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Lin Yang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
